Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age - 09/08/11
on behalf of a Cutivate Lotion Study Group
San Diego, California, and Portland, Oregon
Abstract |
A novel lotion formulation of fluticasone propionate 0.05% has recently become available. Two large, randomized, placebo-controlled, double-blind studies involving 438 subjects demonstrated its efficacy and safety when applied once daily in the treatment of atopic dermatitis in subjects from 3 months to 87 years of age. The studies were limited to 4 weeks duration of use of fluticasone lotion and did not assess longer term efficacy or side effects.
Le texte complet de cet article est disponible en PDF.Plan
The study was sponsored by GlaxoSmithKline, NJ, USA. Cutivate is a trademark of the GSK group of companies. Funding sources: None. Conflicts of interest: None identified. |
Vol 54 - N° 4
P. 715-717 - avril 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?